Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa-Reference-Cited by-同舟云学术

Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Hussein Maytham¹²,Han Mei-Ling¹^ORCID,Zhu Yan¹^ORCID,Zhou Qi³,Lin Yu-Wei¹,Hancock Robert E. W.⁴^ORCID,Hoyer Daniel²⁵⁶,Creek Darren J.⁷^ORCID,Li Jian¹,Velkov Tony²

Affiliation:

1. Monash Biomedicine Discovery Institute, Department of Microbiology, School of Biomedical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia

2. Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia

3. Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, Indiana, USA

4. Department of Microbiology and Immunology, Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada

5. The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia

6. Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA

7. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia

Abstract

In the present study, we employed untargeted metabolomics to investigate the synergistic killing mechanism of polymyxin B in combination with an aminoglycoside, amikacin, against a polymyxin-susceptible isolate of Pseudomonas aeruginosa , FADDI-PA111 (MIC = 2 mg/liter for both polymyxin B and amikacin), and a polymyxin-resistant Liverpool epidemic strain (LES), LESB58 (the corresponding MIC for both polymyxin B and amikacin is 16 mg/liter).

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01587-19

Reference65 articles.

1. World Health Organization. 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland.

2. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

3. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. The University of Chicago Press, Chicago, IL.

4. Lung Infections Associated with Cystic Fibrosis

5. Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Vitro Antimicrobial Synergistic Activity and the Mechanism of the Combination of Naringenin and Amikacin Against Antibiotic-Resistant Escherichia coli;Microorganisms;2024-09-11

2. Antibacterial mechanism of the methanol extract of Thamnolia subuliformis (Ehrh.) W. Culb against Staphylococcus aureus;Letters in Applied Microbiology;2024-07-31

3. Transcriptomic analysis of induced resistance to polymyxin in carbapenem-resistant Enterobacter cloacae complex isolate carrying mcr-9;Journal of Global Antimicrobial Resistance;2024-06

4. Providing insight into the mechanism of action of cationic lipidated oligomers using metabolomics;mSystems;2024-05-16

5. Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics;2024-02-20